Subsequent to approval of the Nomination & Remuneration Committee, the Board of Directors of the Company have, with effect from 01/December/2025, appointed (i) Mr. Rahul Pandey as the President ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sudarshan Pharma Industries has appointed two senior management personnel effective December 1, 2025, following approval from the Nomination & Remuneration Committee. Mr. Rahul Pandey has been appointed as President – Business Operations & Development for the Excipients & API Division, bringing experience from Pfizer Limited, Barentz India, and other pharma firms across Bangladesh, MENA, Korea, Indonesia, and China. Mr. Mayank Vyas has been appointed as President – Business Development Manager, with over 20 years of experience in marketing and HR across construction equipment, tiles, pharma machinery, and chemicals sectors.
The dual senior-level appointments signal a strategic push to strengthen the company's excipients and API business while expanding business development capabilities. Shareholders should view this as a positive step toward operational scaling and revenue diversification, though the impact will depend on execution in coming quarters.